EA201391275A1 - Применение гликопирролата для лечения тахикардии - Google Patents

Применение гликопирролата для лечения тахикардии

Info

Publication number
EA201391275A1
EA201391275A1 EA201391275A EA201391275A EA201391275A1 EA 201391275 A1 EA201391275 A1 EA 201391275A1 EA 201391275 A EA201391275 A EA 201391275A EA 201391275 A EA201391275 A EA 201391275A EA 201391275 A1 EA201391275 A1 EA 201391275A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycopirolat
tachycardia
treatment
application
glycopyrrolate
Prior art date
Application number
EA201391275A
Other languages
English (en)
Other versions
EA025287B1 (ru
Inventor
Сьюзан Снейп
Роберт Тенсли
Original Assignee
СОСЕИ Ар ЭНД Ди ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391275(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103770.2A external-priority patent/GB201103770D0/en
Priority claimed from GBGB1202256.2A external-priority patent/GB201202256D0/en
Application filed by СОСЕИ Ар ЭНД Ди ЛТД. filed Critical СОСЕИ Ар ЭНД Ди ЛТД.
Publication of EA201391275A1 publication Critical patent/EA201391275A1/ru
Publication of EA025287B1 publication Critical patent/EA025287B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

Изобретение относится к новому применению антимускаринового средства гликопирролата, например соли бромида гликопиррония. В частности, изобретение относится к гликопирролату для применения в качестве средства, понижающего частоту сердечных сокращений, и более конкретно, но не исключительно, для применения пациентами, страдающими от респираторных состояний, таких как хроническое обструктивное заболевание легких.
EA201391275A 2011-03-04 2012-03-05 Применение гликопирролата для лечения тахикардии EA025287B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1103770.2A GB201103770D0 (en) 2011-03-04 2011-03-04 Novel use
GBGB1202256.2A GB201202256D0 (en) 2012-02-09 2012-02-09 Novel use
PCT/GB2012/050478 WO2012120284A1 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Publications (2)

Publication Number Publication Date
EA201391275A1 true EA201391275A1 (ru) 2014-02-28
EA025287B1 EA025287B1 (ru) 2016-12-30

Family

ID=45841526

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391275A EA025287B1 (ru) 2011-03-04 2012-03-05 Применение гликопирролата для лечения тахикардии

Country Status (20)

Country Link
US (2) US20140080890A1 (ru)
EP (1) EP2680841B1 (ru)
JP (1) JP6129081B2 (ru)
KR (1) KR101853997B1 (ru)
CN (1) CN103501781B (ru)
AR (1) AR085616A1 (ru)
AU (1) AU2012226608B2 (ru)
BR (1) BR112013022523A2 (ru)
CA (1) CA2828640C (ru)
CL (1) CL2013002542A1 (ru)
EA (1) EA025287B1 (ru)
ES (1) ES2613754T3 (ru)
GE (1) GEP201706640B (ru)
IL (1) IL227972A (ru)
JO (1) JO3510B1 (ru)
MD (1) MD4369C1 (ru)
MX (1) MX356025B (ru)
TW (1) TWI536988B (ru)
WO (1) WO2012120284A1 (ru)
ZA (1) ZA201306130B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2013100009B4 (en) * 2013-01-04 2013-03-14 Novartis Ag Treatment of chronic obstructive pulmonary disease
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
JP6454323B2 (ja) * 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
RS60299B1 (sr) 2014-09-09 2020-07-31 Vectura Ltd Formulacija koja obuhvata glikopirolat, postupak i uređaj
WO2016071862A1 (en) * 2014-11-05 2016-05-12 Glenmark Pharmaceuticals Limited Inhalable pharmaceutical composition comprising glycopyrronium
JP6655169B2 (ja) 2015-09-09 2020-02-26 ベクトゥラ・リミテッド ジェット粉砕法
PL3248646T3 (pl) * 2016-05-25 2021-08-16 Claudia Mattern Dwuczęściowy zestaw półfabrykatu z tworzywa sztucznego
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
BE718438A (ru) * 1967-08-23 1968-12-31
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0909163A4 (en) * 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
GB9808470D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
KR20000013487A (ko) * 1998-08-10 2000-03-06 정주영 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
EP1862164A3 (de) 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
JP5524442B2 (ja) * 2004-02-06 2014-06-18 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US7923455B2 (en) 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2010144628A2 (en) 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Also Published As

Publication number Publication date
CL2013002542A1 (es) 2014-07-11
IL227972A (en) 2017-06-29
AU2012226608A1 (en) 2013-09-12
US20140080890A1 (en) 2014-03-20
NZ614603A (en) 2016-01-29
JP2014514271A (ja) 2014-06-19
ZA201306130B (en) 2014-04-30
AU2012226608B2 (en) 2015-11-26
MD4369C1 (ru) 2016-04-30
KR101853997B1 (ko) 2018-05-02
CA2828640C (en) 2017-01-03
CN103501781A (zh) 2014-01-08
JP6129081B2 (ja) 2017-05-17
MD20130069A2 (ru) 2014-03-31
MX2013009838A (es) 2016-09-27
AR085616A1 (es) 2013-10-16
CA2828640A1 (en) 2012-09-13
TW201247198A (en) 2012-12-01
US20160143880A1 (en) 2016-05-26
EA025287B1 (ru) 2016-12-30
ES2613754T3 (es) 2017-05-25
MX356025B (es) 2018-05-09
IL227972A0 (en) 2013-09-30
GEP201706640B (en) 2017-03-27
TWI536988B (zh) 2016-06-11
EP2680841B1 (en) 2016-12-28
JO3510B1 (ar) 2020-07-05
CN103501781B (zh) 2016-10-26
BR112013022523A2 (pt) 2016-11-29
WO2012120284A1 (en) 2012-09-13
EP2680841A1 (en) 2014-01-08
MD4369B1 (ru) 2015-09-30
US10695321B2 (en) 2020-06-30
KR20140020950A (ko) 2014-02-19

Similar Documents

Publication Publication Date Title
EA201391275A1 (ru) Применение гликопирролата для лечения тахикардии
PH12015501108B1 (en) Treatment of pulmonary disease
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2015DN02573A (ru)
IN2014DN09434A (ru)
EA201201030A1 (ru) 5-алкинилпиримидины
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
WO2013041519A9 (en) Ror gamma modulators
SI2771329T1 (sl) Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni
EA201290374A1 (ru) Аэрозольная композиция для copd
EA201590562A1 (ru) Бензамиды
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
MX350793B (es) Pirroldicarboxamidas condensadas y su uso como agentes farmaceuticos.
NZ703129A (en) Indolecarbonitriles as selective androgen receptor modulators
EA201391211A1 (ru) Новые соединения в качестве лигандов гистаминовых h-рецепторов
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment